Recent studies on CAR T-cell immunotherapy, and the recent approval of a new agent, add to evidence supporting the efficacy of these therapies.
Acute Lymphoblastic Leukemia
T-ALL may be treatable by targeting signaling pathways affected by STIL-TAL1 fusion, according to a team from The Institute of Cancer Research, London, UK.
A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable.
At the NCCN Annual Conference, Dr. Bijal Shah of Tampa’s Moffitt Cancer Center highlighted ongoing challenges in administration of CAR T-cell therapy.
The US Food and Drug Administration has approved blinatumomab (Blincyto) for patients in remission from B-cell precursor ALL with MRD.
Using CRISPR/Cas9 gene editing to remove CD7 from healthy T cells, researchers have found a way to use third party T cells for CAR-T therapy in T-cell hematologic malignancies.
A single infusion of the anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel produced durable remissions in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic lymphoma.
Presence of germline TP53 variants predisposed children to acute lymphoblastic leukemia and was associated with adverse outcomes compared with children who did not have these variants, according to the results of a new study.
Adults with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia are very likely to achieve complete response with intensive combination induction chemotherapy, according to a retrospective review presented at the ASH Annual Meeting.
In this interview ahead of the ASH Annual Meeting we discuss the current management of Philadelphia chromosome–positive acute lymphoblastic leukemia and the role of stem cell transplantation.